MAPK3 and glioblastoma: As shown in Figure 5, SFN significantly activated ERK1/2 in human GBM cells after 48 h treatment, which was in agreement with previous studies that demonstrated SFN-cysteine, an analog of SFN, contributed to the phosphorylation of ERK1/2 in GBM cells [37].